Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 2, 2014
LEXINGTON, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
-
Mar 31, 2014Curis Expects to Reinitiate Enrollment in Single Agent Phase 1 Study of CUDC-427 in Patients With Solid Tumors or Lymphoma
LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
-
Mar 30, 2014
LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
-
Mar 4, 2014
LEXINGTON, Mass., March 4, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
-
Feb 23, 2014
LEXINGTON, Mass., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
-
Feb 20, 2014Management to Host Conference Call Today at 9:00 a.m. EST
LEXINGTON, Mass., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
-
Feb 19, 2014
LEXINGTON, Mass., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
-
Feb 13, 2014
LEXINGTON, Mass., Feb. 13, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
-
Feb 5, 2014
LEXINGTON, Mass., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
-
Dec 9, 2013CUDC-907 (HDAC and PI3K inhibitor) demonstrates preliminary evidence of clinical activity
LEXINGTON, Mass., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...